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Estimating cardiac output 
based on gas exchange 
during veno‑arterial extracorporeal 
membrane oxygenation 
in a simulation study using 
paediatric oxygenators
Kaspar Felix Bachmann1,2*, Rakesh Vasireddy1, Paul Philipp Heinisch3,4, Hansjörg Jenni3, 
Andreas Vogt1 & David Berger2
Veno‑arterial extracorporeal membrane oxygenation (VA‑ECMO) therapy is a rescue strategy for 
severe cardiopulmonary failure. The estimation of cardiac output during VA‑ECMO is challenging. A 
lung circuit ( Q̇Lung) and an ECMO circuit ( Q̇ECMO) with oxygenators for  CO2 removal ( 
.
VCO2) and  O2 uptake 
( 
.
VO2) simulated the setting of VA‑ECMO with varying ventilation/perfusion ( 
.
V/Q̇ ) ratios and shunt. A 




VO2. Q̇ Lung was estimated with a modified 
Fick principle: Q̇Lung = Q̇ECMO × ( 
.






VO2ECMO). A normalization procedure corrected 
.
VCO2 values for a 
.
V/Q̇ of 1. Method agreement was evaluated by Bland–Altman analysis. Calculated Q̇




VO2 correlated well with measured Q̇Lung with a bias of 103 ml/min [− 268 to 
185] ml/min; Limits of Agreement: − 306 ml/min [− 241 to − 877 ml/min] to 512 ml/min [447 to 610 ml/
min],  r2 0.85 [0.79–0.88]). Blood measurements of 
.
VCO2 showed an increased bias (− 260 ml/min 
[− 1503 to 982] ml/min), clinically not applicable. Shunt and 
.
V/Q̇ mismatch decreased the agreement 




VO2 in steady‑state conditions 
allow for clinically applicable calculations of Q̇Lung during VA‑ECMO therapy.
Shock states and lung failure are the most common reasons for admission to an intensive care unit. Both carry 
considerable morbidity and mortality and are amongst the leading causes of death in the developed world. 
Extracorporeal membrane oxygenation (ECMO) has gained widespread interest as a rescue therapy for severe 
pulmonary or circulatory failure and its use grows  exponentially1.
ECMO provides an extracorporeal support for functions of the lung and heart. It may serve as a bridge to 
recovery or long-term mechanical assist devices and transplantation. In a parallel connection to the patient’s 
own circulation, veno-arterial ECMO drains venous blood from the patient into an extracorporeal membrane 
lung, where carbon dioxide is removed and hemoglobin in the red blood cells is oxygenated. The arterialized 
(oxygenated and decarboxylized) blood is pumped back into the patient’s arterial system. It is a concept similar 
to the cardiopulmonary bypass in heart surgery (“heart–lung-machine”), where patients undergo extracorporeal 
circulation on a daily basis. ECMO however is suitable for long-term  support2.
ECMO treatment is technically demanding. In a recent review, refinement of patient inclusion criteria, opti-
mization of additional treatment strategies and weaning strategies were considered research fields of major 
importance for the ongoing improvement for patients on ECMO  treatment3. The physiology of gas exchange and 
blood flow with two competing systems, the ECMO and the patient’s own heart and lung in parallel connection, 
is incompletely  understood4. The goal of the treatment is to maintain tissue perfusion and gas exchange in order 
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to gain time for recovery of native cardiac output (i.e. blood flow through the lungs). The assessment of cardiac 
output under ongoing extracorporeal treatment and especially during weaning, i.e. the stepwise liberation from 
the extracorporeal support, is difficult and mainly based on expert  opinion5,6. Novel experimental approaches 
including modified thermodilution  exist7, but are not validated in a clinical setting. Timing and strategy for 
weaning ECMO are complex  issues5, whereby early weaning is linked to a favorable  outcome1,8,9. During this 
weaning procedure, where 
.
V/Q̇ mismatch is improving, we see the possibility of assessing pulmonary blood flow 
through gas exchange as a useful tool to support the clinician at the bedside.
Recently, we investigated the non-invasive estimation of native cardiac output during ECMO using an adap-
tation of the Fick principle and expiratory gas  measurements10. By conceptually treating the ECMO circuit as a 
right-to-left shunt, we created a mathematical model yielding pulmonary blood flow (i.e. cardiac output) from 
ECMO blood flow and from measurements of carbon dioxide elimination and oxygen consumption ( 
.
VO2 and .
VO2) through the membrane lung and the natural lung. As the ventilation / perfusion ratio ( 
.
V/Q̇ ratio) has a 
major influence on the amount of  CO2  eliminated11,12, we additionally estimated a correction factor to account 
for the non-linearity in  CO2  elimination10.
To confirm our preliminary results and model, we built an in-vitro lung/ECMO simulator by adapting an 
experimental setup developed at the department of Anaesthesiology and Pain Medicine, University Hospital of 
Bern,  Switzerland13. In vitro models have successfully been used to simulate aspects of ECMO therapy such as 
flow  characteristics14, platelet  activation15, delivering of therapeutic  enzymes16 or energy loss due to components 
of the  circuit17.
The aim of this simulator study was to evaluate our modified Fick method under changing 
.
V/Q̇ ratios and 
shunt and to evaluate the influence of these on the accuracy of the method. Furthermore, we compared the carbon 
dioxide contents in the blood and gas phase and their relationship to respective blood flows. According to the 3R 
principles for replacement, reduction, and refinement of the use of animals in experimentation, an additional 
simulation of our preliminary data from a small proof-of-concept study before confirming it in a larger trial will 
allow us to refine our techniques and define the limiting factors for the method more clearly.
Materials and methods
The simulation consisted of two parallel circuits—one representing the ECMO blood flow with extracorporeal 
gas exchange, the other lung and heart—merged into the systemic circulation (Fig. 1). One circuit represents 
the human heart and the lung: It consisted of a micro-diagonal pump (DeltaStream DP-II, Medos, Stolberg, 
Germany), generating non-pulsatile flow, as the heart and an oxygenator  (OxyLung QUADROX-i Pediatric Oxy-
genators; MAQUET, Hirrlingen, Germany) as the natural lung, including a blood flow bypass around the  OxyLUNG 
Figure 1.  In-vitro lung/ECMO simulation. The in-vitro simulation consists of two parallel circuits (ECMO and 
lung) with the ability to shunt  OxyLung. Blood samples could be drawn after  OxyECMO (post membrane), after 
 OxyLung (post lung), from the left atrium (LA), the aorta as well as the right atrium (RA).
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for the simulation of anatomical or functional right-to-left shunt. The second circuit, consisting of the same 
type of pump and oxygenators, represents the ECMO  (OxyECMO). Both oxygenators were operated at a fraction 
of inspired oxygen of 50% throughout the experiment. These two circuits (Lung and ECMO) were merged into 
one mixed flow, representing the Aorta and then guided into a simulated metabolic chamber. Here, over two 
oxygenators  (OxyVCO2/O2, Terumo Capiox RX25R, Ann Arbor, MI, USA) carbon dioxide was introduced into the 
system and oxygen washed out with a nitrogen/carbon dioxide gas blend to ensure venous  pCO2 values between 
50 and 80 mmHg and mixed venous saturations of 70–90%. Gas flows were regulated with high precision flow 
control valves (Vögtlin RED-Y, Basel-Land, Switzerland). Blood was collected in a venous, air-free, reservoir 
bag above the functional right atrium to ensure steady perfusate supply at different blood flow rates. Blood flows 
between the circuits and the shunt were regulated with simple flow restrictors (adjusting nuts).
Priming volume of the system was approximately 2.2 L. It was filled with a mixture of discarded human red 
blood cells and lactated Ringer’s solution in a ratio of 3:1 to reach a hemoglobin value of 8–10 g/L. 50–100 mmol 
of sodium bicarbonate were added to reach physiological pH values between 7.3–7.44. Glucose 20% was added 
to keep glucose level above 5 mmol/l. Boluses of 5000 I. E. Heparin were added every 2–3 h to prevent clotting. 
The system was heated to 36.8 °C using a temperature control system (HCV, Type 20-602, Jostra Fumedica, 
Muri, Switzerland).
Measurements. Exhaust  PECO2 at the ECMO was measured using a standard side-stream capnometer 
(Vamos, Dräger, Lübeck, Germany) with a constant 200 ml/min side-stream flow and a measurement accuracy 
of ± 3.3 mmHg + 8% relative error, as specified by the manufacturer. After every experimental maneuver, blood 
gas samples were drawn at specified ports and analyzed with a point of care device (Cobas b 123, Roche Diag-
nostics, Basel, Switzerland). Blood flows were continuously measured using liquid flow meters (Levitronix, 
Zurich, Switzerland, Fig. 1). Sweep gas flows were set and recorded manually at the gas blenders for  OxyLung and 




Study protocol. Baseline. We aimed at a total flow of 2500 ml in the systemic circulation, measured after 
the metabolic chamber. At baseline, this flow was partitioned in 2000 ml/min running through the ECMO cir-
cuit and 500 ml/min running through the lung circuit. Aortal  pCO2 at baseline was aimed at 40 mmHg corre-
sponding to a simulated  CO2 production of approximately 120–150 ml/min. In a clinical setting the pulmonary 
blood flow is unknown and establishing steady 
.
V/Q̇ or its prediction is not possible. Therefore, lung gas flow was 
kept constant at 1.5 l/min  (FiO2 50%) and remained unchanged during each experimental step.
Step one. From this baseline, multiple weaning trials were performed by 500-ml-wise reductions of ECMO 
blood flow with either a constant 
.
V/Q̇ ratio of 1 (gas flow matches blood flow; Fig. 2 Step 1a) or varying 
.
V/Q̇ 
ratios of 3, 1.5, 1 and 0.75 (constant gas flow of 1.5 l/min during reduction of blood flow; Fig. 2 Step 1b) on the 
ECMO and consecutive increases in lung blood flow 500 ml, matching the ECMO blood flow reduction. These 
maneuvers were repeated for shunt fractions of 0%, and 20% and 40%.
Step two. In a second step—in order to investigate the situation of limited venous return or limited cardiac 
function—lung blood flow was not directly regulated but was the indirect result of changing the venous pool at 
unchanged rotations per minute (RPM; Fig. 2, Step 2a). Cardiac limitation was simulated by adjusting the RPM 
of the Lung pump (Fig. 2, Step 2b). For these second steps, shunt was kept constant at 0%.
Calculations and mathematical model
Blood flow calculations. Based on the ventilation/perfusion ( 
.
V/Q̇ ) concept from respiratory physiology, 
gas exchange of the native lung is proportional to its blood  flow18. The Fick principle and mass balance equations 
(Formula A–C) allow the deduction of formula (1) 10,19:
cv−aoCO2 is the difference between venous and aortal  CO2 content, cv−LACO2 is the difference between 
venous and left atrial  CO2 content, cv−pmCO2 is the difference between venous and post membrane  CO2 
content (Fig. 1)10. By simultaneous measurement of exhaled  CO2 at the lung and  pCO2 at the ECMO gas outlet, 
respective fractions of carbon dioxide elimination ( 
.
VCO2, ECMO and 
.
VCO2, LUNG) can be calculated with simple 
 means10. They should equal the blood carbon dioxide content difference in the respective segment. Rearrange-
ment of formula 1 (formula D–F) proposes a proportional relationship between carbon dioxide elimination and 
respective blood flows:
Qtotal = QLUNG + QECMO (A)
VCO2 total = VCO2 LUNG + VCO2 ECMO (B)
VCO2 LUNG and VCO2 ECMO = Q ×�v−aCO2; VCO2 total = Qtotal ×�ao−vCO2 (C)
(1)Q̇total ×cv−aoCO2 = Q̇LUNG ×cv−LACO2 + Q̇ECMO ×cv−pmCO2.
Qtotal ×�ao−vCO2 = QLUNG ×�v−LACO2 + QECMO ×�v−pmCO2 (D)
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.
VCO2 is the product of the differences in  CO2 times the blood flow and formula 2 can therefore be simplified 
using the following assumptions: V̇CO2LUNG ∼ v−LACO2; V̇CO2ECMO ∼ v−pmCO2; V̇CO2Total ∼ v−aoCO2 . 
The approximation signs are necessary, as 
.
VCO2 is not only determined by the difference in veno-arterial  CO2, 
but also by blood flow. As production and elimination are mathematical opposites, we use absolute values:




(QLUNG + QECMO)×�ao−vCO2 = QLUNG ×�v−LACO2 + QECMO ×�v−pmCO2 (E)











QLUNG = QECMO ×
(|VCO2 ECMO| − |VCO2 total |)
(|VCO2 total | − |VCO2 LUNG|)
(G)







Figure 2.  Step 1a and 1b. Experimental Manoeuvres (Step 1a, 1b, 2a, 2b). In the first part, weaning of ECMO 
blood flow was conducted with reductions of 500 ml and corresponding equal̇ increases of lung blood flow, 
summing up to a systemic blood flow of 2500 ml. The effect of 
.
V/Q̇ was evaluated at a constant and varying 
.
V/Q̇ 
ratio (Step a and b, respectively). Both manoeuvres were triplicated at 0%, 20% and 40% pulmonary shunt. Step 
2a and 2b. A second part investigated the effects of limiting venous return (Step a) or limited pump function 
(step b). Venous return was limited by incomplete transfer of the weaned ECMO blood flow to lung blood flow 
(25% and 50% reduction), leading to venous pooling of blood. Limited cardiac function was simulated by a 
constant RPM at the lung circuit.
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The full deduction of these relationships has previously been  described10.
Blood flow calculations were performed for measurements of 
.





VCO2, normalized at the lung for a 
.
V/Q̇ of 1 ( 
.
VCO2,GasNorm) in order to assess the efficacy of 
the normalization procedure, gaseous measurements of 
.
V  CO2, not normalized ( 
.
VCO2,Gas) in order to simulate 
clinical conditions and 
.





VCO2 towards a 
.
V/Q̇ of 1. Blood flow determines the amount of  CO2 transported 
towards the membrane lung, while ventilation determines the amount of  CO2 eliminated over the respective 
membrane lung. When 
.
V/Q̇ differs from 1, 
.
VCO2 is predominantly determined by  ventilation11 and thus does 
not correlate well with blood flow. This results in different venoarterial content differences across the ECMO and 
lung, which will introduce an error into Eqs. (3) and (4). As we aim to calculate blood flow through the lungs, we 
correct 
.
VCO2 values on the ECMO towards a 
.
V/Q̇ of  110:
The constant c was calculated from a venous blood gas sample [ c = σCO2 × R × T × (1+ Kc)] as a function 
of temperature T, pH  (Kc),  CO2 solubility ( σCO2) and the gas constant  R20. The normalization essentially allows 
to calculate the 
.
VCO2 values only dependent of blood flow and independent of ventilation, i.e. for any given 
.
V
/Q̇-ratio, the normalization calculates the 
.
VCO2 for a 
.
V/Q̇ of 1. In a clinical setting the 
.
V/Q̇ ratio at the ECMO 
is known, therefore 
.
VCO2 at the ECMO is always normalized.
Calculations of shunt and its impact on blood flow calculations. Pulmonary right-to-left shunt 
fraction was calculated as shunt blood flow divided by total lung flow. The relative error in blood flow calcula-
tions resulting from varying shunt was calculated as true blood flow minus calculated blood flow divided by true 
blood flow. Using the Berggren shunt equation with  O2 contents and  CO2 contents, we calculated the estimated 
shunt fractions.
The error produced by the shunt fraction is calculated as:




VO2. Blood  CO2 content  (cCO2) was calculated 
for each sampling port with the method of  Dash21,22.  O2 content  (CO2) was calculated for each sampling port 
using formula (7)  (pO2:  O2 partial pressure [mmHg],  sO2: Saturation, Hb: Hemoglobin [g/L]):
.
VO2 was calculated by multiplying the arterio-venous-
.
Venous  O2 blood content difference with blood flow. 
.
V
CO2 was calculated either from venous-arterial  CO2 content difference multiplied by blood flow ( 
.
VCO2, Blood) or 
from gaseous measurements by multiplying the exhausted  CO2 fraction times the sweep gas flow ( 
.
VCO2, Gas). The 
relationship between 
.
VCO2, Gas and 
.
VCO2, Blood was assessed using multiple linear regression with blood flow ( Q̇ ) 
and differences in  CO2 content (∆cCO2) as independent variables and 
.
VCO2, Gas as dependent variables such as:
Statistical analysis. For statistical, mathematical and graphical analysis, we used Matlab R2020a (Math-
Works, Natick, Massachusetts, USA with an extension for Bland Altman Plots under creative commons 
 license23). Data were not normally distributed and thus presented as median with interquantile [0.25–0.75] 
ranges. Correlation between methods was assessed with linear regression and method agreement with Bland–
Altman  analysis24,25. p < 0.05 was considered significant with two-tailed testing. Linear regression was performed 
using the least square fit method. Correlation coefficients were calculated using Pearson’s square  (r2). The least 
significant change of a method was calculated according to standard  methods26. Multiple linear regression was 
used to assess the relationship between 
.
VCO2, blood flow and differences in  CO2 content.













































(9)V̇CO2Gas = Intercept + β1 ×�cCO2 + β2 × Q + β3 ×�cCO2 × Q.
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Results
Baseline. At the beginning of each experimental step, mixed venous saturation was 87.6 [82.7–88.5] % and 
hemoglobin was 9 [8.5–9.1] g/dl, corresponding to a venous  O2 content of 10.9 [9.7–11.0] ml/100 ml of blood 
and a mixed venous  pCO2 of 48.6 [48.1–51.7] mmHg corresponding to a venous  CO2 content of 68.4 [66.9–89.4] 
ml/100 ml of blood. Arterial oxygen saturation was 99.5 [98.7–100.0] % corresponding to an arterial  O2 content 
of 12.8 [11.7–13.1] ml/100 ml of blood. Arterial  pCO2 was 33.8 [32.3–35.9] mmHg corresponding to an arterial 
 CO2 content of 59.9 [58.7–78.3] ml/100 ml of blood. Arterial and venous pH were 7.39 [7.34–7.47] and 7.28 
[7.24–7.36], respectively.
ECMO  (OxyECMO). Q̇ECMO was 1947 [1786–1942] ml/min. 
.
VCO2, Gas, ECMO was 82.4 [78.4–95.4] ml/min and 
.
V
CO2, Blood, ECMO was 128.0 [114.7–185.3] ml/min. 
.
VO2, Blood, ECMO was 39.5 [32.4–43.3] ml/min. 
.
VECMO was kept 
steady between 1.4 and 1.5 l/min for the maneuvers with a varying 
.
V/Q̇ECMO (steps 1b) and followed blood flow 
in the remaining maneuvers. The correction factor c used in the normalization of 
.
V/Q̇ was 10.4 [9.5–12.5].
Simulated lung  (OxyLung). Q̇Lung was 340 [296 to 464] ml/min with a 
.
VCO2, Gas, Lung of 45.5 [43.1–48.7] ml/min 
while 
.
VCO2, Blood, Lung was 82.0 [69.6–88.8] ml/min. 
.
VO2, Blood, Lung was 7.4 [5.0–9.3] ml/min. Ventilation at the 
lung ( 
.
VLung) was set between 1.4 and 1.5 l/min and remained unchanged.




). Total flow was 2254 [1947–2409] ml/min.  N2 gas flow was kept between 
4 and 6 l/min while  CO2 gas flow was between 300 and 500 ml/min, corresponding to a 
.
VCO2, Blood, Metabolic Chamber 
of 203.5 [173.4–230] ml/min and a 
.
VO2, Blood, Metabolic Chamber of 44.4 [39.6–50.2] ml/min.
Maneuvers and blood flow reductions during step one and two. ECMO  (OxyECMO). In each ma-
neuver, ECMO blood flow was reduced to 25.2% [23.0–25.9] % of baseline. 
.
VO2, Blood, ECMO correlated highly with 
these reductions in ECMO blood flow ( 
.
VO2, Blood, ECMO = 0.02 × ECMO Blood Flow + 5.4,  r2 = 0.785, p < 0.001). 
.
V
CO2, GasNorm, ECMO showed a high correlation with ECMO blood flow ( 
.
VCO2, GasNorm, ECMO = 0.05 × ECMO Blood 
Flow + 1.3,  r2 = 0.963, p < 0.001). Correlation decreased with 
.
VCO2, Gas, ECMO ( 
.
VCO2, Gas, ECMO = 0.04 × ECMO 
Blood Flow + 16.2,  r2 = 0.796, p < 0.001). 
.
VCO2, Blood, ECMO and ECMO Blood flow showed only weak correlations 
( 
.
VCO2, Blood, ECMO = 0.07 × ECMO Blood Flow + 25.8,  r2 = 0.333, p < 0.001).
Simulated lung  (OxyLung). Lung blood flow increased to 1417 [1234–1540] ml/min in Step 1a and 1b, with a 
shunt of 20.5 [18.6–22.2] % in the 20% shunt maneuvers and a shunt of 35.3 [32.7–39.7] % in the 40% shunt 
maneuvers. In step 2a and 2b, lung blood flow increased to a median of 831 [660 to 1254] ml/min..
VO2, Blood, Lung showed high correlations with these increases in lung blood flow ( 
.
VO2, Blood, Lung = 0.02 × Lung 
Blood Flow + 3.7,  r2 = 0.761, p < 0.001). 
.
VCO2, GasNorm, Lung showed a high correlation with lung blood flow ( 
.
V
CO2, GasNorm, Lung = 0.05 × Lung Blood Flow − 4.2,  r2 = 0.986, p < 0.001). With 
.
VCO2, Gas, Lung correlation decreased 
( 
.
VCO2, Gas, Lung = 0.02 × Lung Blood Flow + 40.3,  r2 = 0.673, p < 0.001). Correlations between lung blood flow and .
VCO2, Blood, Lung decreased further ( 
.
VCO2, Blood, Lung = 0.07 × Lung Blood Flow + 60.3,  r2 = 0.189, p = 0.006).




). During Step 1a and Step 1b, blood flow in the metabolic chamber was 
2359 [2004–2487] ml/min and during step 2a and 2b, flow in the metabolic chamber was 1770 [1406–2068] ml/
min. Calculating total  CO2 production/elimination as 
.
VCO2, Blood, Metabolic Chamber minus the sum of 
.
V  CO2, Blood, Lung 
and 
.
VCO2, Blood, ECMO showed a median value of 6.1 [− 2.0 to 13.1] ml/min. Calculating total  O2 consumption and 
transfer as the sum of 
.
VO2, Blood, Lung and 
.
VO2, Blood, ECMO minus 
.
VO2, Blood, Metabolic Chamber showed a median value of 
2.6 [0.3–4.9] ml/min.




VO2 values are presented in Fig. 3. Based on these meas-




VCO2, Gas Norm, 
.
VCO2, Gas and 
.
VCO2, Blood.
Blood flow calculations. Based on 
.
VO2. Linear regression showed high correlations between measured 
and calculated blood flow through the lung circuit using 
.
VO2, Blood values (Calculated Blood Flow = 0.76 × meas-
ured Blood Flow + 120 ml/min,  r2 = 0.88, p < 0.001, Fig. 4A). The positive bias (103 ml/min) indicated an under-
estimation of measured blood flow. The least significant change was 95 ml/min. Exclusion of shunt values (> 1%) 
increased the accuracy of the method and cancels underestimation (Calculated Blood flow = 1.08 × measured 




VCO2, GasNorm. Linear regression showed high correlations for simulated Q̇Lung calculations using 
.
V
CO2GasNorm, which is corrected for a 
.
V/Q̇ of 1 at  OxyLung as well as  OxyECMO (Calculated Blood Flow = 0.88 × 
measured Blood Flow − 72 ml,  r2 = 0.85, p < 0.001, Fig. 4B). The calculated bias (185 ml/min) is positive, indi-
cating an underestimation of measured blood flow. The least significant change was 100 ml/min. Exclusion of 
shunt values (> 1%) increased the accuracy of the method (Calculated Blood flow = 0.87 × measured Blood Flow 
− 157.76 ml/min,  r2 0.96, p < 0.001, Bias 56 ml/min [Upper Limit 299 ml, Lower Limit − 187 ml/min]).
Based on 
.
VCO2, Gas. Regression coefficients decreased, when 
.
VCO2, Gas was only normalized at  OxyECMO but 
not at  OxyLung to calculate simulated blood flows through the lung circuit, as would be the case in a clinical set-
ting (Calculated Blood Flow = 0.45 × measured Blood Flow + 728 ml/min,  r2 = 0.79, p < 0.001, Fig. 4C). The bias 
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(− 268 ml/min) is negative and the lack of normalization leads to a significant relationship between the mean 
and the difference of methods (Difference of Method = 0.69 × Bias − 932,  r2 = 0.72, p < 0.001), leading to an over-
estimation of blood flow at low flows and an underestimation of blood flows at high flows. This corresponds to 
the change in 
.
V/Q̇ , e.g. low 
.
V/Q̇ at high blood flow and high 
.
V/Q̇ at low blood flow. Exclusion of shunt values 
(> 1%) increased the slope of the regression but does otherwise not affect the accuracy of the method (Calculated 
Blood flow = 2.14 × measured Blood Flow + 1671 ml/min,  r2 0.90, p < 0.001, Bias − 333 ml/min [Upper Limit 
256 ml/min, Lower Limit − 921 ml/min]).
Figure 3.  Stairs plot showing measured data from performed experiment with manoeuvres Step 1a, Step 1b, 
Step 2a and Step 2b. Note that in Step 2b, Cardiac Limitation there only 3 data points due to pump failure.
8
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VCO2, Blood. Blood flow calculations with 
.
VCO2, Blood show high inaccuracy with no significant rela-
tionship between measured lung circuit flow and calculated lung circuit flow (Calculated Blood Flow = 0.08 × 
measured Blood Flow + 1150 ml,  r2 = 0.01, p = 0.49, Fig. 4D), corresponding to a bias at − 268 ml/min with wide 
limits of agreement (− 1503 ml to 967 ml/min). There is no improvement in accuracy through exclusion of shunt 
values (Calculated Blood flow = 0.24 × measured Blood Flow + 538 ml,  r2 0.04, p = 0.4, Bias − 409 ml/min [Upper 
Limit 724 ml/min, Lower Limit − 1541 ml/min]).
Impact of shunt. 
.
VO2, Blood, Lung. There is a significant relationship between shunt values and the produced 
error from measured blood flow (Error = 0.87 × Shunt − 0.9%,  r2 = 0.7, p < 0.001, Fig. 5A).
.
VCO2, GasNorm, Lung. The influence of shunt on blood flow calculations is not only present in calculations using .
VO2, Blood, Lung values but also 
.
VCO2, GasNorm, Lung values (Error = 1.11 × Shunt − 3.8%,  r2 = 0.75, p < 0.001, Fig. 5B).
Using classical Berggren shunt equations, we can show that determining shunt fractions is possible with both 
 CO2 and  O2 contents, with more variance in  CO2 calculations (O2: Calculated shunt = 0.88 × Set Shunt + 0.33%, 




VCO2GasNorm normalized for ECMO and Lung to a 
.
V/Q̇ 
of 1 (B), 
.
VCO2Gas not normalized at the Lung (C) and 
.
VCO2Blood (D). Mean and upper/lower are depicted 
within each graph. Circles, squares, triangles up and down refer to the 4 different maneuvers performed. Color 
indicates shunt with blue representing 0% shunt and yellow representing maximum shunt (42.4%).
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 r2 = 0.792, p < 0.001;  CO2: Calculated shunt = 0.96 × Set Shunt + 0.35%,  r2 = 0.653, p < 0.001). Comparing set shunt 
to calculated shunt shows a bias of 1.08% for  O2 derived shunt (Lower Limit: − 13.03%, Upper Limit 15.2%) and 
a bias of 0.08% for  CO2 derived shunt (Lower Limit: − 21.15%, Upper Limit 21.31%).
Blood flow calculations using 
.
VCO2, Gas (Error = 0.44 × Shunt − 43.7%,  r2 = 0.01, p = 0.605, Fig. 5C) and 
.
V
CO2, Blood (Error = 0.81 × Shunt − 63.3%,  r2 = 0.02, p = 0.498, Fig. 5D) do not show enough accuracy in order to 
determine the influence of shunt.
Relationship between  CO2 content in blood, blood flow and 
.
VCO2, Gas, calculated for  OxyECMO 
and  OxyLung. 
.
VCO2, Blood overestimates 
.
VCO2, Gas with a bias of 50 ml/100 ml blood (Fig. 6A). The wide limits 
of agreement (Lower Limit − 71 ml/100 ml blood, Upper Limit 171 ml/100 ml blood) show that 
.
VCO2, Blood is 
inconsistent and unreliable. 
.
VCO2GasNorm shows similar bias (62 ml/100 ml blood) and limits of agreement (− 61 
to 184 ml/100 ml blood), but Fig. 6B shows that the spread of data is more uniform. Exclusion of shunt values 
(> 1%) reduced bias to 24 ml/100 ml blood [− 32 to 80 ml/100 ml blood] for 
.
VCO2Gas and a bias of 32 ml/100 ml 
blood [− 28 to 91 ml/100 ml blood]..
VCO2, Blood is the product of the difference in  CO2 content (Delta  cCO2) and blood flow. Multiple linear 




VCO2, GasNorm and these components of 
.
VCO2, Blood with 
both high  r2 and significance (Table 1, Fig. 6C,D). The multiple linear regression on 
.
VCO2GasNorm results in Delta 
 cCO2 being non-significant.




V  CO2GasNorm normalized for ECMO 
and Lung to a 
.
V/Q̇ of 1 (B), 
.
VCO2Gas not normalized at the Lung (C) and 
.
VCO2Blood (D). Maneuvers simulating 
cardiac limitation and limited venous return are excluded, because they did not include any shunt per protocol.
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VCO2Gas. (B) Bland–Altman plot for 
.
VCO2Blood against .
VCO2GasNorm. Multiple regression analysis showing the relationship between Blood Flow, Delta in  CO2 Content 
and 
.
VCO2Gas (C) and 
.
VCO2GasNorm (D). Regression coefficients can be found in Table 1. Values from  OxyECMO 
are blue while values from  OxyLung are in orange color.
Table 1.  Multiple linear regression according to model specified in formula 8 for 
.
VCO2Gas  (r2 = 0.743, 
p < 0.001) and 
.









Intercept 12.397 0.019 0.75 0.763
β1—Delta  cCO2 (ml/100 min) − 1.007  < 0.001 0.17 0.170
β2—Blood Flow (ml) 0.039  < 0.001 0.05 < 0.001
β3—Delta  cCO2 × blood flow 0.0003 0.309 − 0.0002 0.242
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Discussion
Our simulation of two competing blood circuits (ECMO and lung) with a deoxygenation and carboxylation unit 
(metabolic chamber) was able to reach physiologically representative parameters regarding gas exchange and 
blood content of carbon dioxide and oxygen. The blood flows in this experiment are adequate for the pediatric 
oxygenators and the simulated 
.
VO2. As the main result, we could calculate simulated pulmonary blood flow with 
high accuracy and precision and correlations using 
.
VCO2, GasNorm and 
.
VO2, Blood values. This confirms our main 
hypothesis that gas exchange may be used for blood flow calculations in extracorporeal circuits. The underly-
ing physiological principles and mass conservation show that  CO2 production and  O2 consumption must be 
in equilibrium in two competing systems with two circuits and oxygenators, which allows calculation of blood 
flow within certain  limits10. The mass balance equations do not necessarily pose a need for the calculation with 
absolute values as suggested by Eqs. (3) and (4). The absolute values make the interpretation of results easier, 
since they cancel out directional (I. E. elimination or production) effects of gas exchange on the direction of 
calculated blood flow, as we have previously  published10. The accuracy of these flow calculations is impaired by 
high shunt and 
.
V/Q̇ mismatch. Shunted blood will not participate in gas exchange and is therefore not detected 
by our method. We showed that the simulated pulmonary shunt has a linear relationship to the difference in  CO2 
content as it does with  O2 content. This shunt contributes to inaccuracy in our model. A shunt of 100%, which 
is possible upon initiation of ECMO therapy, would therefore produce a calculated blood flow of 0 ml/min. The 
linear regressions of Fig. 5A,B estimate an error of 86.7% and 107.2% respectively for an assumed shunt of 100%, 
which confirms this assumption. In the three-compartment model of the  lung27, shunt or venous admixture is 
seen as the cause of hypoxemia, while excessive dead space ventilation with exhaustion of respiratory reserves 
explains  hypercapnia27. Our results indicate that increased arterial  pCO2 could be caused by shunt as well, when 
the alveolar minute ventilation stays constant, as it would be the case during controlled mechanical ventilation.
Blood flow through the oxygenator and 
.
VCO2, Gas and 
.
VO2, Blood show a strong correlation. Mass conservation 
implies that Eqs. (3) and (4) are only true if two prerequisites are met: First, the inflow content into both circuits 
needs to be equal and second, the difference in gas content across the lung and the ECMO must be the same. 
If 
.
V/Q̇ ratio at the ECMO and the lung are not equal, the second prerequisite is not met due to the influence 
of ventilation on the veno-arterial content  difference11,12. Therefore, the best result using carbon dioxide based 
calculations is achieved with 
.
VCO2, GasNorm for both lung and ECMO, where content differences are normalized 
for inequalities introduced by  ventilation10. High 
.
V /Q will lead to an overestimation of pulmonary blood flow 
and low 
.
V/Q̇ will lead to an underestimation (Fig. 5C).




VO2 in the gas 





VO2 in the gas phase (formula 3 and 4). The slope of the grids in Fig. 6C represent 
the proportionality between the differences in blood gas content and 
.
VCO2, Gas. Both models for the simple as 
well as the normalized gas measurement show high goodness of fit. The model for 
.
VCO2Gas shows the delta in 
 CO2 content as well as blood flow as significant determinants whereas after the normalization, only blood flow 
remains as a significant factor. If blood flow remains steady, different 
.
VCO2 values will result from different 
ventilation settings, i.e. varying 
.
V/Q̇ ratios are traversed. This results in varying blood  CO2 content differences 
for the same blood flow. As a side note, this may have a major effect on v-a  PCO2 gradients, which are proposed 
for monitoring of the  microcirculation28.
The normalization shown in Fig. 6D discards the effect of the difference in  CO2 content and fully reestablishes 
the relationship in Eqs. (3) and (4). This improves the accuracy of our blood flow estimations, since varying 
.
V/Q̇ 
ratios are corrected for and the normalization reestablishes equal differences in gas content across the ECMO 
and the lung. This method for normalization was previously  described10.
Such a normalization seems unnecessary for 
.
VO2, as oxygen is primarily transported by binding to hemo-
globin (formula 7). As long as post oxygenator saturation reaches 100%, 
.
VO2 is independent of 
.
V/Q̇ ratio and 
represents blood flow, thus the difference and gas content across the ECMO and the lung are the same. Only if 
hemoglobin were to become incompletely saturated, ventilation would have an influence on 
.
VO2. An increase 
in  FiO2 will correct this phenomenon, unless a functional shunt  exists29.
Blood flow calculations for 
.
VCO2, Blood are not reliable because there is no normalization applied and calcu-
lating the  CO2 blood content can be challenging, since mathematical models do not represent the underlying 
physical chemistry  completely30,31. Gas measurements are easily done and calculating 
.
VCO2 from exhaust cap-





VCO2Blood, which proves the underlying physiological principle.
In our previously published animal series with this new  method10, we used the differences in 
.
VCO2 and blood 
flow during weaning, as the experimental setup did not allow to reach a steady state. In the present simulation 
study—using a highly controllable environment—such a steady state could be reached quickly. Therefore, we 
validated our method using these steady state conditions rather than differences in gas change during weaning. 
We interpret the small content differences in the 
.
VCO2, Blood and 
.
VO2, Blood at the metabolic chamber and the 
lung and membrane contents as limits of the calculation models rather than expressions of non-steady state.
Transferring our findings to a clinical setting would imply that the estimations of pulmonary blood flow 
during ECMO weaning are possible using  FiO2, exhaust  pCO2/pO2, 
.
Venous pH, ECMO blood flow, ECMO 
ventilation, lung alveolar ventilation and lung dead space. The two latter parameters are readily available using 
volumetric  capnography33,34, and all of these parameters can easily be measured in an intensive care unit where 
ECMO therapy is performed. Our method is limited by high shunt and 
.
V/Q̇ mismatch, which we can only par-
tially correct for. In a clinical setting, the 
.
V/Q̇ ratio at the lung would remain unknown, but 
.
VCO2Gas at the lung 
might be corrected using alternative estimations of 
.
V/Q̇ . Multiple approaches exist such as  MIGET35, electrical 
impedance tomography and positron emission  tomography36, even though they are not in widespread clinical 
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use. High precision measurements of gas exchange at the lung might increase the precision of our  approach37. 
We would therefore suggest that our method will have the most benefit during ECMO weaning, when in general 
the patient’s 
.
V/Q̇ mismatch has improved.
This study has multiple limitations: Firstly, we calculate simulated pulmonary blood flow using a high fidel-
ity in-vitro simulation and the transfer to a clinical setting might be limited. Secondly, we have not performed 
gaseous measurements of 
.
VO2. However, from a physiological point of view these should correlate well with 
measurements of 
.
VO2 in the blood phase. Thirdly, our calculations of  VCO2, Blood show a high bias and wide 
limits of agreement with 
.
VCO2, Gas. This is in contrast to recent  findings38, where 
.
VCO2, Blood correlated well with .
VCO2, Gas. In our model, this mismatch may be owed to the fact that we used a red cell suspension and not whole 
blood. The missing serum fraction may have influenced the content  calculation31. Figure 6 suggests that the dif-
ferences could also be caused by 
.
V/Q̇ mismatch and shunt, because calculations excluding shunt shows its influ-
ence on these differences. Fourthly, the here proposed method assesses the heart and lung function of a patient 
simultaneously as a functional unit. If during ECMO weaning the cardiac output assessed with our method is not 
sufficient, further diagnosis should help clarifying the underlying pathophysiology. In case of weaning failure due 
to left and right ventricular dysfunction, valvular dysfunction, incomplete filling or insufficient venous return 
echocardiography as well as pulmonary catheterization should be  considered5.
Conclusions
This in-vitro study explored the relationships between blood gas content  (CO2 and  O2), blood flow and the 
elimination of these gases. We show that gas exchange during ECMO weaning might help in predicting the 
pulmonary blood flow. Our method could easily be transferred into a clinical setting, but would be limited if 
there are high shunts of blood in the lung or a high 
.
V/Q̇ mismatch.
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